Bethyl Laboratories
Rabbit anti-BTF IHC Antibody Affinity Purified
Primary
Catalog #IHC-00080
TargetBTF
HostRabbit
ClonalityPolyclonal
ReactivityHuman
ApplicationIHC
Image 1 of 1
local_shipping
Order within 7 hours and 26 minutes for shipment by Tuesday, November 24
Product Description
BTF is a transcriptional repressor that interacts with Bcl-2 related proteins to promote apoptosis. BTF has also been found to interact with emerin, a nuclear protein implicated in the muscle wasting disease Emery-Dreifuss muscular dystrophy.
Specifications
Clonality
Polyclonal
Host
Rabbit
Immunogen
Between 175 and 225
Isotype
IgG
Reactivity
Human
Format
Whole IgG
Conjugate Type
Unconjugated
Purity
Antigen Affinity Purified
Concentration
250 µg/ml
Target Identity
TargetBTF
Antigen Species
Human
Gene ID9774
Gene Symbol
BCLAF1
Gene Name
BCL2 associated transcription factor 1
Uniprot IDQ9NYF8
Protein Name
Bcl-2-associated transcription factor 1
Alternate Names
Product Information
Applications
IHC
Buffer
Tris-buffered Saline containing 0.1% BSA and 0.09% Sodium Azide
Storage Conditions
2 - 8 °C
Physical State
Liquid
Shelf Life
1 year from date of receipt
Country of Origin
USA
Production & Epitope
Antibody was affinity purified using an epitope specific to BTF immobilized on solid support.
The epitope recognized by IHC-00080 maps to a region between residue 150 and 200 of human BCL2-Associated Transcription Factor 1 using the numbering given in entry NP_055554.1 (GeneID 9774).
Applications
Epitope exposure is recommended.
Immunohistochemistry (IHC)1:100 - 1:500
Documents
Safety Data SheetPDF · IHC-00080Open
Product DatasheetPDF · IHC-00080 · Lot 1 (current lot)Open
Product DatasheetPDF · IHC-00080 · Lot 1 (current lot)Open
Services
Antibody Conjugation
Antibody and conjugate formats developed together, built to your specification.
Request CustomizationCustom Monoclonal Antibody Discovery Services
Full custom monoclonal development, from immunization through validation.
Explore Monoclonal DevelopmentVHH Discovery
Single-domain antibodies for structurally difficult targets a conventional monoclonal can't reach.
Explore VHH DiscoveryResources
1



